This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article relies largely or entirely on a single source. Relevant discussion may be found on the talk page. Please help improve this article by introducing citations to additional sources.Find sources: "Tetroxoprim" – news · newspapers · books · scholar · JSTOR (August 2014) This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: "Tetroxoprim" – news · newspapers · books · scholar · JSTOR (August 2014) (Learn how and when to remove this template message) (Learn how and when to remove this template message)
Tetroxoprim
Clinical data
ATC code
Identifiers
  • 5-[3,5-Dimethoxy-4-(2-methoxyethoxy)benzyl]pyrimidine-2,4-diamine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.053.427 Edit this at Wikidata
Chemical and physical data
FormulaC16H22N4O4
Molar mass334.376 g·mol−1
3D model (JSmol)
  • COCCOC1=C(C=C(C=C1OC)CC2=CN=C(N=C2N)N)OC
  • InChI=1S/C16H22N4O4/c1-21-4-5-24-14-12(22-2)7-10(8-13(14)23-3)6-11-9-19-16(18)20-15(11)17/h7-9H,4-6H2,1-3H3,(H4,17,18,19,20) ☒N
  • Key:WSWJIZXMAUYHOE-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Tetroxoprim (INN) is a derivative of trimethoprim. It was first described in 1979.[1]

References

  1. ^ Aschhoff HS, Vergin H (November 1979). "Tetroxoprim—a new inhibitor of bacterial dihydrofolate reductase". J Antimicrob Chemother. 5 (B): 19–25. doi:10.1093/jac/5.supplement_b.19. PMID 43863.